Back to overview

Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral control.

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Duhan Vikas, Khairnar Vishal, Friedrich Sarah-Kim, Zhou Fan, Gassa Asmae, Honke Nadine, Shaabani Namir, Gailus Nicole, Botezatu Lacramioara, Khandanpour Cyrus, Dittmer Ulf, Häussinger Dieter, Recher Mike, Hardt Cornelia, Lang Philipp A, Lang Karl S,
Project Analysis of RAG-dependent immunodeficiency and autoimmunity
Show all

Original article (peer-reviewed)

Journal Scientific reports
Volume (Issue) 6
Page(s) 19191 - 19191
Title of proceedings Scientific reports
DOI 10.1038/srep19191


Clinically used human vaccination aims to induce specific antibodies that can guarantee long-term protection against a pathogen. The reasons that other immune components often fail to induce protective immunity are still debated. Recently we found that enforced viral replication in secondary lymphoid organs is essential for immune activation. In this study we used the lymphocytic choriomeningitis virus (LCMV) to determine whether enforced virus replication occurs in the presence of virus-specific antibodies or virus-specific CD8(+) T cells. We found that after systemic recall infection with LCMV-WE the presence of virus-specific antibodies allowed intracellular replication of virus in the marginal zone of spleen. In contrast, specific antibodies limited viral replication in liver, lung, and kidney. Upon recall infection with the persistent virus strain LCMV-Docile, viral replication in spleen was essential for the priming of CD8(+) T cells and for viral control. In contrast to specific antibodies, memory CD8(+) T cells inhibited viral replication in marginal zone but failed to protect mice from persistent viral infection. We conclude that virus-specific antibodies limit viral infection in peripheral organs but still allow replication of LCMV in the marginal zone, a mechanism that allows immune boosting during recall infection and thereby guarantees control of persistent virus.